Key Scientific and Clinical Insights Leading to Cerevance's Pursuit of Solengepras

Pharmaceutical Executive: What key scientific or clinical insights led Cerevance to pursue Solengepras?
Craig Thompson: Solengepras is the first non-dopaminergic medication to treat Parkinson's disease. How we really uncovered this was from an early platform that we had, and later we confirmed it with our NETSseq platform. And what makes it really unique is, as I mentioned, it's non dopaminergic, so you're starting to see efficacy above what we see with other oral medications, actually starting to approach what we see with infusions, but because it's non dopaminergic, we're not seeing the side effects, at least in early clinical trials, that we see with dopamine related products. So we're not seeing things like orthostatic hypertension, dyskinesia, which is the kind of random flinging of the arms and things of that nature. So it's been very, very well tolerated, and we are seeing, really, I'd say, so far, kind of best in class efficacy.